Merck, Inc.
A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Atorvastatin in Healthy Adult Participants (MK-0616-024)
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 18
- Registration Number
- NCT06699355
- Locations
- 🇺🇸
Celerion (Site 0001), Lincoln, Nebraska, United States
A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014)
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT06698016
- Locations
- 🇺🇸
Altasciences Clinical Kansas, Inc. (Site 0001), Overland Park, Kansas, United States
A Clinical Study of MK-3475A to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
- Conditions
- Interventions
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 160
- Registration Number
- NCT06698042
- Locations
- 🇬🇹
CELAN,S.A ( Site 1104), Guatemala, Guatemala
🇬🇹Private Practice- Dr. Rixci Augusto Lenin Ramírez ( Site 1102), Guatemala, Guatemala
🇰🇷Pusan National University Hospital ( Site 3002), Pusan Kwangyokshi, Pusan-Kwangyokshi, Korea, Republic of
A Clinical Study of Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-025)
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 40
- Registration Number
- NCT06691906
- Locations
- 🇺🇸
Celerion (Site 0001), Lincoln, Nebraska, United States
A Clinical Study of MK-4318 and Diltiazem in Healthy People (MK-4318-003)
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 19
- Registration Number
- NCT06692647
- Locations
- 🇺🇸
Labcorb CRU, Madison (Site 0001), Madison, Wisconsin, United States
A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 72
- Registration Number
- NCT06688058
A Study of MK-1084 Human Absorption, Distribution, Metabolism, and Excretion in Healthy Adult Participants (MK-1084-006)
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 8
- Registration Number
- NCT06687759
- Locations
- 🇺🇸
Fortea CRU Madison (Site 0001), Madison, Wisconsin, United States
A Study of the Effects of Itraconazole on the Plasma Levels of Nemtabrutinib (MK-1026-013)
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 15
- Registration Number
- NCT06688045
- Locations
- 🇺🇸
Labcorp Clinical Research Unit Inc. (Site 0001), Honolulu, Hawaii, United States
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
- Conditions
- Interventions
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 81
- Registration Number
- NCT06686394
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
- Conditions
- Interventions
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 3082
- Registration Number
- NCT06667700
- Locations
- 🇺🇸
Absolute Clinical Research ( Site 3709), Phoenix, Arizona, United States
🇺🇸Paradigm Clinical Research, LLC ( Site 3785), San Diego, California, United States
🇺🇸Millennium Clinical Trials ( Site 3758), Westlake Village, California, United States